BioSpace News Archive

NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that its DERMAdoctor product collections will be featured at Cosmoprof North America, a leading business-to-business (B2B) beauty trade show being held July 12-14 at the Las Vegas Convention Center.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), today announced the submission of a New Drug Application (NDA) at the end of June to the U.S. Food and Drug Administration (FDA) seeking approval for NOV03 (perfluorohexyloctane).

Parkinson Canada in partnership with the Davis Phinney Foundation is excited to launch the first Canadian version of the Every Victory Counts® manual, a comprehensive resource aimed at helping the 100,000 Canadians living with Parkinson’s to maintain and improve their quality of life.

Arsham Sheybani , MD of Washington University and Lori Pacheco of Orbis to discuss Mitosol®.

Appoints Manfred Kraus , Ph.D. as Vice President of Research and Development.

Meridian Bioscience, Inc. (“Meridian” or the “Company”) (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary results for its third quarter of fiscal 2022.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of stock options to purchase 120,500 shares of its common stock and the grant of 80,400 restricted stock units to four new employees.

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that the first patient was treated at the David C. Pratt Cancer Center at Mercy Hospital St. Louis on July 5th with the MEVION S250i Proton Therapy System ® .

Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, announced that members of its executive team will participate at the following investor conferences.

Meridian Bioscience, Inc and SD Biosensor, Inc. (“SDB”) (KOSE: A137310) and SJL Partners LLC (“SJL”) (collectively, the “Consortium”) announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an all-cash transaction valued at approximately $1.53 billion.